BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,039 filers reported holding BAXTER INTL INC in Q1 2015. The put-call ratio across all filers is 0.65 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $209,945 | -1.0% | 4,119 | +4.5% | 0.15% | -31.5% |
Q3 2022 | $212,000 | -16.2% | 3,941 | 0.0% | 0.22% | -31.3% |
Q2 2022 | $253,000 | -17.3% | 3,941 | 0.0% | 0.32% | +1.3% |
Q1 2022 | $306,000 | -9.5% | 3,941 | 0.0% | 0.32% | -11.6% |
Q4 2021 | $338,000 | +6.6% | 3,941 | 0.0% | 0.36% | -32.1% |
Q3 2021 | $317,000 | +456.1% | 3,941 | +228.4% | 0.53% | +241.0% |
Q3 2016 | $57,000 | +5.6% | 1,200 | 0.0% | 0.16% | -8.2% |
Q2 2016 | $54,000 | +10.2% | 1,200 | 0.0% | 0.17% | +3.7% |
Q1 2016 | $49,000 | +6.5% | 1,200 | 0.0% | 0.16% | +12.3% |
Q4 2015 | $46,000 | +15.0% | 1,200 | 0.0% | 0.15% | +11.5% |
Q3 2015 | $40,000 | -52.4% | 1,200 | 0.0% | 0.13% | -47.2% |
Q2 2015 | $84,000 | +2.4% | 1,200 | 0.0% | 0.25% | +4.6% |
Q1 2015 | $82,000 | -6.8% | 1,200 | 0.0% | 0.24% | -4.4% |
Q4 2014 | $88,000 | +2.3% | 1,200 | 0.0% | 0.25% | +6.9% |
Q3 2014 | $86,000 | 0.0% | 1,200 | 0.0% | 0.23% | +5.5% |
Q2 2014 | $86,000 | -3.4% | 1,200 | 0.0% | 0.22% | -8.3% |
Q1 2014 | $89,000 | +6.0% | 1,200 | 0.0% | 0.24% | +9.1% |
Q4 2013 | $84,000 | +6.3% | 1,200 | 0.0% | 0.22% | -4.3% |
Q3 2013 | $79,000 | -4.8% | 1,200 | 0.0% | 0.23% | -3.4% |
Q2 2013 | $83,000 | – | 1,200 | – | 0.24% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |